Study Identifies Promising Drug Target in Certain Breast and Ovarian Cancers
Dana-Farber Cancer InstituteStudy by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider – and offers a ready means of identifying them.